Cereno Scientific strives to disrupt cardiovascular treatments worldwide by unlocking the potential of epigenetic modulation...| Cereno Scientific
Sitemap| Cereno Scientific
CS1-003 is a Phase IIa trial evaluating the safety, tolerability, pharmacokinetics, and exploratory efficacy of CS1 on top of standard-of-care in patients with PAH. The study, which was performed at 10 clinical sites in the US, randomized 25 patients to CS1 treatment, | Cereno Scientific